Volume : 13, Issue : 07, July – 2026
Title:
MEDICATION-ASSOCIATED HYPERURICEMIA AND INCREASED PROTEINURIA FOLLOWING CONCOMITANT USE OF HYDROCHLOROTHIAZIDE-BASED ANTIHYPERTENSIVE THERAPY AND DAPAGLIFLOZIN IN A PATIENT WITH TYPE 2 DIABETES MELLITUS: A CASE REPORT
Authors :
Dr. Asfia Mohammed Raffi, PharmD*, Dr. Amina Sarwat, Dr. Omer Bin Amer, Dr. Maria Nooreen, Dr. Syeda Baseera Fatima, Dr. Fathima Riyaz, Dr. L.M. Sneha Judith
Abstract :
Background: Medication-related adverse effects are common in patients with diabetes and hypertension receiving multiple drugs. Hydrochlorothiazide-containing antihypertensive medications may increase serum uric acid levels, while careful renal monitoring is recommended in patients receiving dapagliflozin.
Case Presentation: A 60-year-old female with a history of type 2 diabetes mellitus, hypertension, and dyslipidemia presented with intermittent giddiness. During follow-up evaluation, laboratory investigations revealed elevated serum uric acid (7.5 mg/dL) and an increased urine protein-creatinine ratio (0.45). The patient was receiving a hydrochlorothiazide-based antihypertensive regimen along with dapagliflozin. After reviewing the medication profile, the hydrochlorothiazide-containing therapy was discontinued and replaced with an alternative antihypertensive combination. The patient was advised adequate hydration and regular monitoring of renal function and metabolic parameters.
Conclusion: This case highlights the importance of routine monitoring for hyperuricemia and proteinuria in patients receiving hydrochlorothiazide-based antihypertensive therapy with dapagliflozin. Early identification and timely modification of therapy can help prevent further renal complications and improve patient outcomes.
Keywords: Hyperuricemia, Proteinuria, Hydrochlorothiazide, Dapagliflozin, Type 2 Diabetes Mellitus, Adverse Drug Reaction, Case Report.
Cite This Article:
Please cite this article in press Asfia Mohammed Raffi et al., Medication-Associated Hyperuricemia And Increased Proteinuria Following Concomitant Use Of Hydrochlorothiazide-Based Antihypertensive Therapy And Dapagliflozin In A Patient With Type 2 Diabetes Mellitus: A Case Report., Indo Am. J. P. Sci, 2026; 13(07).
REFERENCES:
1. Zhai Z, Yang Y, Lin G, Lin W, Wu J, Liu X, Zhang S, Zhou Q, Liu H, Hao G. The hypertension and hyperlipidemia status among type 2 diabetic patients in the community and influencing factors analysis of glycemic control. Diabetol Metab Syndr. 2023 Apr 13;15(1):73.
2. AlQashqri H. Renally Inappropriate Medications in the Old Population: Prevalence, Risk Factors, Adverse Outcomes, and Potential Interventions. Cureus. 2023 Nov 20;15(11):e49111
3. Joshi P, Rick G, Mesineni S, Bohara S, Atif S, Poonthottam N, Azam A, Mehmood Y, Ali R, Raquib N, Sasikumar A, Khalid A, Anyagwa OE. Antihypertensive therapy in diabetes mellitus: efficacy, safety, and metabolic impacts in type 1 and type 2 diabetes. Cardiovasc Diabetol Endocrinol Rep. 2026 Feb 18;12(1):4
4. Chen XY, Lu F, Zhang J, Xu CX, Du XF, Liang MB, Chen LJ, Zhong JM. The effect of hyperuricemia and its interaction with hypertension towards chronic kidney disease in patients with type 2 diabetes: evidence from a cross- sectional study in Eastern China. Front Endocrinol (Lausanne). 2024 Jul 29;15:1415459.
5. Tahrani AA, Barnett AH. Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. Diabetes Ther. 2010 Dec;1(2):45-56
6. Agarwal R, Verma A, Georgianos PI. Diuretics in patients with chronic kidney disease. Nat Rev Nephrol. 2025 Apr;21(4):264-278.
7. Vandell AG, McDonough CW, Gong Y, Langaee TY, Lucas AM, Chapman AB, Gums JG, Beitelshees AL, Bailey KR, Johnson RJ, Boerwinkle E, Turner ST, Cooper-DeHoff RM, Johnson JA. Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study. J Intern Med. 2014 Nov;276(5):486-97
8. Koshida T, Suzuki H, Murkoashi M, Takahara H, Suzuki Y, Gohda T. Effect of dapagliflozin on proteinuria and the slope of the estimated glomerular filtration rate in patients with immunoglobulin A nephropathy: A multicenter prospective study. J Int Med Res. 2025 Sep;53(9):3000605251376895.
9. Hosoya T, Kuriyama S, Yoshizawa T, Kobayashi A, Otsuka Y, Ohno I. Effects of combined antihypertensive therapy with losartan/hydrochlorothiazide on uric acid metabolism. Intern Med. 2012;51(18):2509-14
10. Fujisaki K, Tsuruya K, Nakano T, Taniguchi M, Higashi H, Katafuchi R, Kanai H, Nakayama M, Hirakata H, Kitazono T; Impact of Combined Losartan/Hydrochlorothiazide on Proteinuria in Patients with Chronic Kidney Disease and Hypertension (ILOHA) Study Investigators. Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. Hypertens Res. 2014 Nov;37(11):993-8.
11. Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG, Wong MG, Gansevoort RT, Heerspink HJL; DIAMOND investigators. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5. Erratum in: Lancet Diabetes Endocrinol. 2020 Aug;8(8):e3.
12. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013 Sep;15(9):853-62.
13. Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015 Apr 19;16:58.
14. Liu X, Qiu Y, Li D, Tan J, Liang X, Qin W. Effectiveness of Drug Treatments for Lowering Uric Acid on Renal Function in Patients With Chronic Kidney Disease and Hyperuricemia: A Network Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2021 Aug 3;12:690557.